Antifungal therapy with voriconazole improves outcome in patients with invasive pulmonary aspergillosis and chronic obstructive pulmonary disease

Guinea J., Torres-Narbona M., Gijón P., de Miguel J., Muñoz P., Peláez T., Bouza E.

Author address: 



Objectives: Invasive pulmonary aspergillosis (IPA) in patients with chronic obstructive pulmonary disease (COPD) is an emerging fungal infection with a high mortality rate, despite antifungal therapy. However, first-line antifungal therapy for IPA in this population has not been properly established. We determined risk factors that predict poor outcome in patients with COPD and IPA, with emphasis on the role of antifungal therapy. Methods: From November 1999 to March 2008, we evaluated 57 cases of probable IPA in patients with COPD. We reviewed their charts for clinical features, bacterial co-infections, analytical data, previous use of corticosteroids/antibacterial agents before the isolation of Aspergillus, antifungal treatment, and outcome. Results: The 57 patients with IPA showed an overall mortality of 71.9%. We detected 4 independent variables able to predict poor outcome (P

abstract No: 

P 1747

Full conference title: 

19th European Congress of Clinical Microbiology and Infectious Diseases
    • ECCMID 19th (2009)